Bivalirudin
- Generic Name
- Bivalirudin
- Brand Names
- Angiomax
- Drug Type
- Small Molecule
- Chemical Formula
- C98H138N24O33
- CAS Number
- 128270-60-0
- Unique Ingredient Identifier
- TN9BEX005G
- Background
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
- Indication
For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
- Associated Conditions
- Thrombosis
A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: pegnivacogin/anivamersen
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Regado Biosciences, Inc.
- Target Recruit Count
- 3232
- Registration Number
- NCT01848106
- Locations
- 🇺🇸
Black Hills Cardiovascular Research, Rapid City, South Dakota, United States
BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.
- Conditions
- Percutaneous Coronary InterventionAcute Myocardial Infarction
- Interventions
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 2194
- Registration Number
- NCT01696110
- Locations
- 🇨🇳
1 st Hosp. of Anhui Med Univ., Hefei, Anhui, China
🇨🇳Anhui Provincial Hosp., Hefei, Anhui, China
🇨🇳3rd Hosp. of Beijing Univ., Beijing, Beijing, China
Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH
- Conditions
- Transcatheter Aortic Valve ReplacementAortic Valve ReplacementSevere Aortic Stenosis
- Interventions
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 803
- Registration Number
- NCT01651780
- Locations
- 🇨🇦
Montreal Heart Institute, Montreal, Quebec, Canada
🇨🇦St. Paul´s Hospital Providence Health Care, Vancouver, Canada
🇫🇷Centre Hospitalier de Lyon, Bron, France
Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 204
- Registration Number
- NCT01555658
- Locations
- 🇮🇹
Dept.of Cardiovascular Sciences Policlinico Umberto I, Rome, Italy
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
- Conditions
- Acute ST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2015-05-13
- Target Recruit Count
- 1829
- Registration Number
- NCT01519518
- Locations
- 🇬🇧
Liverpool Heart and Chest Hospital, Liverpool, Merseyside, United Kingdom
Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2014-04-08
- Lead Sponsor
- Clinica Mediterranea
- Target Recruit Count
- 837
- Registration Number
- NCT01465503
- Locations
- 🇮🇹
IRCCS Policlinico Multimedica, Milan, Italy
🇮🇹Clinica Mediterranea, Naples, Italy
Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 260
- Registration Number
- NCT01464671
- Locations
- 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 2198
- Registration Number
- NCT01087723
- Locations
- 🇦🇹
Magistratsabeilung 70, Wiener, Wien, Austria
🇦🇹Universitats-Klinik Fur, Wien, Austria
🇩🇰Odense Universitets Hospital, Odense, Denmark
EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Laval University
- Target Recruit Count
- 2000
- Registration Number
- NCT01084993
- Locations
- 🇨🇦
Quebec Heart-Lung Institute, Quebec, Canada
Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 548
- Registration Number
- NCT00976092
- Locations
- 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Bavaria, Germany
🇩🇪Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Bavaria, Germany
🇩🇪Herzzentrum der Segeberger Kliniken, Bad Segeberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.